Form 4: Galectin Therapeutics Director Kevin D Freeman Acquires 10,000 Shares
SEC Form 4 Filing
Director Kevin D Freeman reports acquisition of 10,000 shares of Galectin Therapeutics at $0.8134 per share.
Summary
- On December 24, 2024, Kevin D Freeman, a director of Galectin Therapeutics Inc. [GALT], acquired 10,000 shares of common stock at a price of $0.8134 per share.
- Following the transaction, Freeman directly owns 44,769 shares.
- Freeman also indirectly owns 80,000 shares through Freeman Global Holdings LLC and 18,063 shares through an IRA.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. It's a routine disclosure of insider buying, which can be interpreted as a positive signal, but it's not a major event.
Positives
- Director's purchase may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company insider believes the company's stock is undervalued.
Stakeholder Impact
- The purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 12/24/2024 | Date of transaction: Purchase of 10,000 shares of common stock. |
| 12/26/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.